Total company revenue fell from a peak of $19.3 billion in 2022 to $3.2 billion for the full year ended Dec. 31, 2024. For ...

Shares of Moderna finished March 11 down by 93% from their peak in 2021. In addition to its COVID-19 vaccine, Moderna markets ...

JPMorgan analyst Jessica Fye lowered the firm’s price target on Moderna (MRNA) to $33 from $40 and keeps an Underweight rating on the shares, ...

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.

Feb 28 (Reuters) - Britain's health regulator said on Friday it has approved Moderna's (MRNA.O), opens ... Sign up here. RSV is a common virus that spreads very easily and causes infections ...

"The MHRA's authorization of our RSV vaccine is an important milestone for Moderna's efforts toward respiratory disease preparedness," said Stéphane Bancel, Chief Executive Officer of Moderna.

mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA ...

Moderna is facing several headwinds, including the declining COVID-19 vaccine and the soft sales performance of its recently launched RSV vaccine. There have also been several third-party reports ...

Moderna Inc.’s stock erased early losses to gain more than 3% on Friday, after the biotech company posted a wider-than-expected fourth-quarter loss and offered soft guidance for 2025, offsetting ...

Adding to Moderna's woes, its highly anticipated respiratory syncytial virus (RSV) vaccine, known as mRESVI and approved by the Food and Drug Administration (FDA) in 2024 as the company's only ...